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Objective. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI) is a promising treatment in upper
aerodigestive malignancies. EGFR inhibitors might be more eﬀective in patients whose tumors harbor speciﬁc EGFR mutations.
The presence of speciﬁc EFGR mutations is predictive of over a 75% response rate to TKI therapies as compared to 10% in wild
typecasesofnon-smallcelllungcancer.Ourobjectivewastoexaminewhetherthesemutationsmightoccurinupperaerodigestive
cancers. Design. DNA was extracted from 20 head and neck squamous cell tumors and 4 squamous cell carcinoma cell lines and
sequenced the receptor using published primer pairs. We then compared the results against published mutations. Results.N oe x o n
19 or 21 mutations were found in any of the 20 tumors and 0 of 4 cell lines. Based on the tumor data we would predict that no
greaterthan8%ofheadandnecktumors(CI97.5%)wouldbelikelytoharboreitherofthesemutations.Conclusions.Ourﬁndings
are comparable to results recently published of Korean, Austrian, and Spanish patient populations and we conclude that exon 19
and 21 EGFR mutations are not more common in head and neck cancer than in nonsmall-cell carcinoma.
Copyright © 2009 Matthew Carlson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Upper aerodigestive cancers including oral cavity, pharynx,
and laryngeal malignancies aﬀects an estimated 3 million
patients worldwide yearly [1]. Carcinogenesis has been
linked to the overuse of tobacco and alcohol [2]; more
recently the human papillomavirus has been implicated
[3]. Unfortunately, the cure rates for these malignancies
have remained stagnant for several decades, and so new
therapies for this malignancy are integral to controlling this
disease.
Overthepastdecade,theemergenceoftargetedtherapies
represents a new development in the treatment of solid
tumor malignancies [4–10] .S e v e r a la g e n tc l a s s e sh a v eb e e n
used to improve survival in a variety of tumor types, and
EGFR-disruptive therapies have had promising results in
lung cancer in speciﬁc patient populations [11–14]. In head
and neck carcinoma, EGFR directed antibody therapy has
been approved for simultaneous use with radiation therapy
for improved survival of advanced stage disease [15]. Other
clinical trials with these agents suggest response rates for
recurrent or metastatic head and neck cancer may be similar
to studies in lung cancer [16, 17].
In lung cancer, it has recently been reported that tumors
harboring mutations of exon 19 and 21 were associated with
improved clinical response rates [18]. In the present study,
we examined 20 head and neck cancer specimens and 4 cell
lines for mutations in either exon and report here the high
conservation of these sequences of the EGFR gene.
2.MaterialsandMethods
Tumor specimens were obtained through the University
of Minnesota tissue procurement facility in compliance
under University of Minnesota Institutional Review Board
approval. To remain within human investigation HIPAA
compliant guidelines established for the tissue procurement
facility, these tumors were supplied without patient identify-
ing data. The tumors were derived from primary cancers of
the upper aerodigestive tact (oral cavity, oropharynx, larynx,
and hypopharynx). Head and neck cancer demographics
for our university patient population are typical: 2 : 12 International Journal of Otolaryngology
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Figure 1: Mutational hotspots in EGFR gene clustering at ATP-binding pocket. The above sequences contain the 2 primary sites of interest
for mutation analysis. The areas in red represent the regions where mutations most often occur. The mutation in exon 19 is most commonly
a deletion mutation, while the mutation seen in exon 21 is a missense mutation (T → G substitution at nucleotide 2573 resulting in a L858R
amino acid substitution).
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Figure 2: Chromatograms of PCR products. (a) graphs displaying exon 19 sense and antisense strands on top and bottom, respectively. (b)
Graphs displaying exon 21 sense and antisense strands on top and bottom respectively. In both exons 19 and 21 no signiﬁcant double peaks
were obtained signifying the absence of any mutations within these reading frames.
male to female preponderance, average age = 60years.
Approximately 5% of the tumors in our tumor bank are
from underrepresented minority populations, a reﬂection
of our regional referral base. Between 2002 and 2003, 20
randomly selected frozen specimens from patients with
pathologically conﬁrmed head and neck squamous cell
carcinoma (HNSCC), along with 4 squamous carcinoma
cell lines (CA-9-22, NA, UM-SCC-9, UM-SCC-11B), were
obtained for DNA analysis.
For mutational analysis of the EGFR coding sequence
for exons 19 and 21, DNA extraction was performed
using the Wizard Genomic DNA Puriﬁcation Kit (Promega,
Madison, WI) according to the manufacturer’s instructions.
Forward and reverse primers were made for both of the
EGFR mutational hotspots located on exons 19 and 21.
Previously published primer sequences [18] were synthe-
sized by Integrated DNA Technologies (Coralville, IA).
PCR ampliﬁcation was carried out using AmpliTaq Gold
Polymerase (Applied Biosystems, Foster City, CA) and an
MJ Research thermocycler (Bio-Rad, Hercules, CA). PCR
cycling parameters were 95◦C hot start for 9 minutes, then
94◦C for 30 seconds, 60◦C for 1minutes, and 72◦Cf o r4 5
seconds for a total of 25 cycles, followed by a ﬁnal extension
step of 72◦C for 5 minutes. PCR product puriﬁcation was
carried out using Purelink PCR Puriﬁcation Kit (Invitrogen,
Carlsbad, CA). UV spectrophotometry was then used to
assure quality and calculate DNA sample concentration. The
resulting DNA was then sent for sequencing at the University
ofMinnesotaMicrochemicalSequencingfacility.Sequencing
results were viewed and compared with published sequences
using Chromas software (Technelysium Pty Ltd, Tewantin
QLD, Australia).
2.1. Statistics. The Fisher Exact test was used to compare
the published frequency of mutations in a recently pub-
lished lung cancer study using Prism GraphPad 4 Software
(GraphPad, San Diego, CA). To calculatethe 95% conﬁdence
interval (CI) for a proportion, we used the exact method for
a binomial parameter [19].
3. Results
High-quality DNA was isolated from all 20 tumor samples
and4celllines.PCRanalysisofexons19and21yielded100%
homology between the nucleotide sequences in question.International Journal of Otolaryngology 3
No mutations were found in the 20 tumor samples or the
four cell lines. There was no statistical diﬀerence (P = .5)
between published rates of EGFR mutations in NSCLC [18]
and our data. Next, we calculated a 95% conﬁdence interval
based on the presence of 0% mutations in either exon 19 or
21. Based on a 0% mutation rate, we would predict that no
greater than 17% of head and neck tumors would be likely to
harbor mutations at exon 19 or 21.
4. Discussion
These data demonstrate that only a small number of head
and neck tumors are likely to have mutations of EGFR
receptor exons 19 and 21. Mutations of exons 19 and 21
are the most common EGFR receptor mutations in lung
cancer and confer receptor tyrosine kinase activation [11,
18]. It is postulated that tumors harboring EGFR mutations
demonstrate inﬂexible “tumor addiction” to the high EGFR
transduction environment since they were born out of this
condition. TKIs disrupt the primary prosurvival signaling
pathway and lead to rapid tumor cell death [20]. A number
of recent studies in head and neck cancer demonstrate a
low, but signiﬁcant, level of clinical response (up to 12%) of
singleagentEGFRTKI,inasettingofrecurrentormetastatic
disease [21, 22]. Since activating EGFR mutations at exons
19 and 21 is highly associated with a good clinical response
to EGFR inhibitors in lung cancer, the fact that our tumor
specimens do not demonstrate these mutations may support
therelativelylowlevelsofclinicalresponseinrecentheadand
neck cancer clinical studies. Since 0% of our specimens and
cell lines were associated with mutations, we extrapolated a
95% conﬁdence interval for the likely number of head and
neck tumor specimens in a similar large population of U.S.
head and neck cancer patients. We would predict that no
more than 17% of head and neck tumors would be likely
to harbor a mutation at either exon 19 or 21. These results
are comparable to 3 small studies demonstrating that EGFR
mutations occur in very few-sampled HNSCC in Korean
[23], Austrian [24], and Spanish [25] patients. Further, our
data also predicts that these mutations should not occur
more often than similar mutations in NSCLC.
Since TKI therapy is expensive and primarily beneﬁts a
minority of patients receiving it as a single agent, it would
be very useful to predict which patients are most likely to
receive beneﬁt. Because these agents are most successful in
patients whose tumors harbor activating mutations, empiric
TKItherapyforallpatientswithrecurrentormetastatichead
and neck cancer is impractical. Screening patients for TKI
sensitive mutations may allow for more eﬃcient therapy and
improved patient outcomes.
The tumor patients in our population are fairly typical
head and neck cancer patients when segregated for age,
gender, and tobacco use. However, the location of our cancer
center in the U.S. Midwest has relatively low numbers of
non-Caucasian patients in our clinical trials and specimen
banks pool (approximately 5%), a number that reﬂects
the demographics of our 4 state referral pattern. Another
limitation to our study is the fact that the tumor specimens
are supplied without identifying data from the patients, per
human investigation regulations of the tumor bank. In spite
of these limitations, it is helpful to know that since no muta-
tions exist at either locus in our samples, it might suggest
that only a minority of such patients will likely respond to
current EGFR-directed therapies. Further investigations in
HNSCCcorrelatingexons19and21mutationstatusandTKI
response are required.
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